| 000 | 01641 a2200481 4500 | ||
|---|---|---|---|
| 005 | 20250517065858.0 | ||
| 264 | 0 | _c20161012 | |
| 008 | 201610s 0 0 eng d | ||
| 022 | _a1873-2518 | ||
| 024 | 7 |
_a10.1016/j.vaccine.2015.11.048 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aWagenvoort, Gertjan H J | |
| 245 | 0 | 0 |
_aRisk and outcomes of invasive pneumococcal disease in adults with underlying conditions in the post-PCV7 era, The Netherlands. _h[electronic resource] |
| 260 |
_bVaccine _cJan 2016 |
||
| 300 |
_a334-40 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAdolescent |
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 | _aAged, 80 and over |
| 650 | 0 | 4 |
_aBacteremia _xepidemiology |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 |
_aHeptavalent Pneumococcal Conjugate Vaccine _xadministration & dosage |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 |
_aMeningitis, Bacterial _xepidemiology |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aNetherlands _xepidemiology |
| 650 | 0 | 4 |
_aPneumococcal Infections _xepidemiology |
| 650 | 0 | 4 | _aRisk Assessment |
| 650 | 0 | 4 | _aSerogroup |
| 650 | 0 | 4 |
_aStreptococcus pneumoniae _xclassification |
| 650 | 0 | 4 | _aSurvival Analysis |
| 650 | 0 | 4 | _aYoung Adult |
| 700 | 1 | _aKnol, Mirjam J | |
| 700 | 1 | _ade Melker, Hester E | |
| 700 | 1 | _aVlaminckx, Bart J | |
| 700 | 1 | _avan der Ende, Arie | |
| 700 | 1 | _aRozenbaum, Mark H | |
| 700 | 1 | _aSanders, Elisabeth A M | |
| 773 | 0 |
_tVaccine _gvol. 34 _gno. 3 _gp. 334-40 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1016/j.vaccine.2015.11.048 _zAvailable from publisher's website |
| 999 |
_c25523353 _d25523353 |
||